Cellular Activation in the Immune Response of Sarcoidosis

 

 Buy Article Permissions and Reprints

Abstract

Sarcoidosis is a chronic granulomatous disorder characterized by an accumulation of lymphocytes and macrophages in the alveoli. Ultimately, long-lasting, nontreated disease results in a distortion of the microarchitecture of the lower respiratory tract. Our current understanding of its pathogenesis is that several sequential immunological events finally resulting in granuloma formation are involved: (1) dependent on a susceptible genetic background described by a variety of functional polymorphisms (2) the exposure to one or several still elusive antigen(s), leads to (3) an activation of macrophages, (4) an attainment of T cell immunity against the antigen(s) mediated by antigen processing and presentation by macrophages, and finally to (5) induction of granuloma formation. In this article, a detailed review on cellular and molecular mechanisms underpinning the sarcoid granulomatous lesion will be given. The important role of alveolar macrophages, T lymphocytes, regulatory T cells, and various cytokines/chemokines in orchestrating the induction, evolution, and immunoregulation of the sarcoid granulomatous/fibrotic lesions will be underscored. Although an etiological agent for sarcoidosis has not been identified, plausible “sarcoid antigens” including mycobacterial antigens such as mKatG or ESAT-6, antigens from Propionibacterium acnes, or even self-antigens will be discussed. It is possible that not one single causative agent exists but several germs, microbial products, or inorganic substances might induce pathogenetic mechanisms leading to a disease called sarcoidosis.

• References

• 1 Spagnolo P, Grunewald J. Recent advances in the genetics of sarcoidosis. J Med Genet 2013; 50 (5) 290-297
  CrossrefPubMedGoogle Scholar
• 2 Müller-Quernheim J, Schürmann M, Hofmann S , et al. Genetics of sarcoidosis. Clin Chest Med 2008; 29 (3) 391-414 , viii
  CrossrefPubMedGoogle Scholar
• 3 Iannuzzi MC, Maliarik MJ, Poisson LM, Rybicki BA. Sarcoidosis susceptibility and resistance HLA-DQB1 alleles in African Americans. Am J Respir Crit Care Med 2003; 167 (9) 1225-1231
  CrossrefPubMedGoogle Scholar
• 4 Rybicki BA, Maliarik MJ, Poisson LM , et al. The major histocompatibility complex gene region and sarcoidosis susceptibility in African Americans. Am J Respir Crit Care Med 2003; 167 (3) 444-449
  CrossrefPubMedGoogle Scholar
• 5 Grunewald J, Janson CH, Eklund A , et al. Restricted V alpha 2.3 gene usage by CD4+ T lymphocytes in bronchoalveolar lavage fluid from sarcoidosis patients correlates with HLA-DR3. Eur J Immunol 1992; 22 (1) 129-135
  CrossrefPubMedGoogle Scholar
• 6 Oswald-Richter K, Sato H, Hajizadeh R , et al. Mycobacterial ESAT-6 and katG are recognized by sarcoidosis CD4+ T cells when presented by the American sarcoidosis susceptibility allele, DRB1*1101. J Clin Immunol 2010; 30 (1) 157-166
  CrossrefPubMedGoogle Scholar
• 7 Nguyen T, Liu XK, Zhang Y, Dong C. BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation. J Immunol 2006; 176 (12) 7354-7360
  CrossrefPubMedGoogle Scholar
• 8 Valentonyte R, Hampe J, Huse K , et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 2005; 37 (4) 357-364
  CrossrefPubMedGoogle Scholar
• 9 Zissel G, Ernst M, Schlaak M, Müller-Quernheim J. Accessory function of alveolar macrophages from patients with sarcoidosis and other granulomatous and nongranulomatous lung diseases. J Investig Med 1997; 45 (2) 75-86
  PubMedGoogle Scholar
• 10 Adrianto I, Lin CP, Hale JJ , et al. Genome-wide association study of African and European Americans implicates multiple shared and ethnic specific loci in sarcoidosis susceptibility. PLoS ONE 2012; 7 (8) e43907
  CrossrefPubMedGoogle Scholar
• 11 Li Y, Wollnik B, Pabst S , et al. BTNL2 gene variant and sarcoidosis. Thorax 2006; 61 (3) 273-274
  CrossrefPubMedGoogle Scholar
• 12 Rybicki BA, Walewski JL, Maliarik MJ, Kian H, Iannuzzi MC ; ACCESS Research Group. The BTNL2 gene and sarcoidosis susceptibility in African Americans and Whites. Am J Hum Genet 2005; 77 (3) 491-499
  CrossrefPubMedGoogle Scholar
• 13 Ishihara M, Ohno S, Ishida T , et al. Genetic polymorphisms of the TNFB and HSP70 genes located in the human major histocompatibility complex in sarcoidosis. Tissue Antigens 1995; 46 (1) 59-62
  CrossrefPubMedGoogle Scholar
• 14 Seitzer U, Swider C, Stüber F , et al. Tumour necrosis factor alpha promoter gene polymorphism in sarcoidosis. Cytokine 1997; 9 (10) 787-790
  CrossrefPubMedGoogle Scholar
• 15 Feng Y, Zhou J, Gu C , et al. Association of six well-characterized polymorphisms in TNF-α and TNF-β genes with sarcoidosis: a meta-analysis. PLoS ONE 2013; 8 (11) e80150
  CrossrefPubMedGoogle Scholar
• 16 Somoskövi A, Zissel G, Seitzer U, Gerdes J, Schlaak M, Müller-Quernheim J. Polymorphisms at position -308 in the promoter region of the TNF-alpha and in the first intron of the TNF-beta genes and spontaneous and lipopolysaccharide-induced TNF-alpha release in sarcoidosis. Cytokine 1999; 11 (11) 882-887
  CrossrefPubMedGoogle Scholar
• 17 Vasakova M, Sterclova M, Kolesar L , et al. Cytokine gene polymorphisms and BALF cytokine levels in interstitial lung diseases. Respir Med 2009; 103 (5) 773-779
  CrossrefPubMedGoogle Scholar
• 18 Zissel G, Homolka J, Schlaak J, Schlaak M, Müller-Quernheim J. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am J Respir Crit Care Med 1996; 154 (3 Pt 1) 713-719
  CrossrefPubMedGoogle Scholar
• 19 Krein PM, Winston BW. Roles for insulin-like growth factor I and transforming growth factor-beta in fibrotic lung disease. Chest 2002; 122 (6, Suppl): 289S-293S
  CrossrefPubMedGoogle Scholar
• 20 Sgonc R, Wick G. Pro- and anti-fibrotic effects of TGF-beta in scleroderma. Rheumatology (Oxford) 2008; 47 (Suppl. 05) v5-v7
  CrossrefPubMedGoogle Scholar
• 21 Prud'homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007; 87 (11) 1077-1091
  CrossrefPubMedGoogle Scholar
• 22 Muraközy G, Gaede KI, Zissel G, Schlaak M, Müller-Quernheim J. Analysis of gene polymorphisms in interleukin-10 and transforming growth factor-beta 1 in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18 (2) 165-169
  PubMedGoogle Scholar
• 23 Gaede KI, Amicosante M, Schürmann M, Fireman E, Saltini C, Müller-Quernheim J. Function associated transforming growth factor-beta gene polymorphism in chronic beryllium disease. J Mol Med (Berl) 2005; 83 (5) 397-405
  CrossrefPubMedGoogle Scholar
• 24 Kruit A, Grutters JC, Ruven HJ , et al. Transforming growth factor-beta gene polymorphisms in sarcoidosis patients with and without fibrosis. Chest 2006; 129 (6) 1584-1591
  CrossrefPubMedGoogle Scholar
• 25 Pabst S, Fränken T, Schönau J , et al. Transforming growth factor-beta gene polymorphisms in different phenotypes of sarcoidosis. Eur Respir J 2011; 38 (1) 169-175
  CrossrefPubMedGoogle Scholar
• 26 Crouser ED, Julian MW, Crawford M , et al. Differential expression of microRNA and predicted targets in pulmonary sarcoidosis. Biochem Biophys Res Commun 2012; 417 (2) 886-891
  CrossrefPubMedGoogle Scholar
• 27 Pabst S, Baumgarten G, Stremmel A , et al. Toll-like receptor (TLR) 4 polymorphisms are associated with a chronic course of sarcoidosis. Clin Exp Immunol 2006; 143 (3) 420-426
  CrossrefPubMedGoogle Scholar
• 28 Pabst S, Bradler O, Gillissen A, Nickenig G, Skowasch D, Grohe C. Toll-like receptor-9 polymorphisms in sarcoidosis and chronic obstructive pulmonary disease. Adv Exp Med Biol 2013; 756: 239-245
  PubMedGoogle Scholar
• 29 Veltkamp M, van Moorsel CH, Rijkers GT, Ruven HJ, Grutters JC. Genetic variation in the Toll-like receptor gene cluster (TLR10-TLR1-TLR6) influences disease course in sarcoidosis. Tissue Antigens 2012; 79 (1) 25-32
  CrossrefPubMedGoogle Scholar
• 30 Veltkamp M, Grutters JC, van Moorsel CH, Ruven HJ, van den Bosch JM. Toll-like receptor (TLR) 4 polymorphism Asp299Gly is not associated with disease course in Dutch sarcoidosis patients. Clin Exp Immunol 2006; 145 (2) 215-218
  CrossrefPubMedGoogle Scholar
• 31 Agostini C, Meneghin A, Semenzato G. T-lymphocytes and cytokines in sarcoidosis. Curr Opin Pulm Med 2002; 8 (5) 435-440
  CrossrefPubMedGoogle Scholar
• 32 Nicod LP, Cochand L, Dreher D. Antigen presentation in the lung: dendritic cells and macrophages. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17 (3) 246-255
  PubMedGoogle Scholar
• 33 Agerberth B, Grunewald J, Castaños-Velez E , et al. Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. Am J Respir Crit Care Med 1999; 160 (1) 283-290
  CrossrefPubMedGoogle Scholar
• 34 Zissel G, Bäumer I, Fleischer B, Schlaak M, Müller-Quernheim J. TCR V beta families in T cell clones from sarcoid lung parenchyma, BAL, and blood. Am J Respir Crit Care Med 1997; 156 (5) 1593-1600
  CrossrefPubMedGoogle Scholar
• 35 Darlington P, Haugom-Olsen H, von Sivers K , et al. T-cell phenotypes in bronchoalveolar lavage fluid, blood and lymph nodes in pulmonary sarcoidosis—indication for an airborne antigen as the triggering factor in sarcoidosis. J Intern Med 2012; 272 (5) 465-471
  CrossrefPubMedGoogle Scholar
• 36 Crowley LE, Herbert R, Moline JM , et al. “Sarcoid like” granulomatous pulmonary disease in World Trade Center disaster responders. Am J Ind Med 2011; 54 (3) 175-184
  CrossrefPubMedGoogle Scholar
• 37 Izbicki G, Chavko R, Banauch GI , et al. World Trade Center “sarcoid-like” granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest 2007; 131 (5) 1414-1423
  CrossrefPubMedGoogle Scholar
• 38 Jordan HT, Stellman SD, Prezant D, Teirstein A, Osahan SS, Cone JE. Sarcoidosis diagnosed after September 11, 2001, among adults exposed to the World Trade Center disaster. J Occup Environ Med 2011; 53 (9) 966-974
  CrossrefPubMedGoogle Scholar
• 39 Kveim AM. the date is OK, page numbers are 169-172. Nord Med 1941; 9: 169-172
  PubMedGoogle Scholar
• 40 Chase MW, Siltzbach LE. Concentration of the active principle responsible for the Kveim reaction. La Sarcoidose, Rapp IV ^e Conf intern 1967: 150-153
  PubMedGoogle Scholar
• 41 Mitchell DN. The nature and physical characteristics of a transmissible agent from human sarcoid tissue. Ann N Y Acad Sci 1976; 278: 233-248
  CrossrefPubMedGoogle Scholar
• 42 Mitchell DN, Rees RJ, Goswami KK. Transmissible agents from human sarcoid and Crohn's disease tissues. Lancet 1976; 2 (7989) 761-765
  PubMedGoogle Scholar
• 43 Mitchell DN. Mycobacteria and sarcoidosis. Lancet 1996; 348 (9030) 768-769
  CrossrefPubMedGoogle Scholar
• 44 Moller DR. Potential etiologic agents in sarcoidosis. Proc Am Thorac Soc 2007; 4 (5) 465-468
  CrossrefPubMedGoogle Scholar
• 45 Maertzdorf J, Weiner III J, Mollenkopf HJ , et al; TBornotTB Network. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci U S A 2012; 109 (20) 7853-7858
  CrossrefPubMedGoogle Scholar
• 46 Abe C, Iwai K, Mikami R, Hosoda Y. Frequent isolation of Propionibacterium acnes from sarcoidosis lymph nodes. Zentralbl Bakteriol Mikrobiol Hyg [A] 1984; 256 (4) 541-547
  PubMedGoogle Scholar
• 47 Eishi Y, Suga M, Ishige I , et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol 2002; 40 (1) 198-204
  CrossrefPubMedGoogle Scholar
• 48 Wahlström J, Dengjel J, Persson B , et al. Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J Clin Invest 2007; 117 (11) 3576-3582
  CrossrefPubMedGoogle Scholar
• 49 Wahlström J, Dengjel J, Winqvist O , et al. Autoimmune T cell responses to antigenic peptides presented by bronchoalveolar lavage cell HLA-DR molecules in sarcoidosis. Clin Immunol 2009; 133 (3) 353-363
  CrossrefPubMedGoogle Scholar
• 50 Müller-Quernheim J, Gaede KI, Fireman E, Zissel G. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients. Eur Respir J 2006; 27 (6) 1190-1195
  CrossrefPubMedGoogle Scholar
• 51 Zissel G, Prasse A, Müller-Quernheim J. Immunologic response of sarcoidosis. Semin Respir Crit Care Med 2010; 31 (4) 390-403
  Article in Thieme ConnectPubMedGoogle Scholar
• 52 Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81 (1) 1-5
  CrossrefPubMedGoogle Scholar
• 53 Pechkovsky DV, Zalutskaya OM, Ivanov GI, Misuno NI. Calprotectin (MRP8/14 protein complex) release during mycobacterial infection in vitro and in vivo. FEMS Immunol Med Microbiol 2000; 29 (1) 27-33
  CrossrefPubMedGoogle Scholar
• 54 Korthagen NM, Nagtegaal MM, van Moorsel CH, Kazemier KM, van den Bosch JM, Grutters JC. MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases. Clin Exp Immunol 2010; 161 (2) 342-347
  PubMedGoogle Scholar
• 55 Bargagli E, Olivieri C, Prasse A , et al. Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. Inflammation 2008; 31 (5) 351-354
  CrossrefPubMedGoogle Scholar
• 56 Veress B, Malmsköld K. The distribution of S100 and lysozyme immunoreactive cells in the various phases of granuloma development in sarcoidosis. Sarcoidosis 1987; 4 (1) 33-37
  PubMedGoogle Scholar
• 57 Riva M, Källberg E, Bjork P , et al. Induction of nuclear factor-κB responses by the S100A9 protein is Toll-like receptor-4-dependent. Immunology 2012; 137 (2) 172-182
  CrossrefPubMedGoogle Scholar
• 58 Yonekawa K, Neidhart M, Altwegg LA , et al. Myeloid related proteins activate Toll-like receptor 4 in human acute coronary syndromes. Atherosclerosis 2011; 218 (2) 486-492
  CrossrefPubMedGoogle Scholar
• 59 Ashitani J, Matsumoto N, Nakazato M. Elevated alpha-defensin levels in plasma of patients with pulmonary sarcoidosis. Respirology 2007; 12 (3) 339-345
  CrossrefPubMedGoogle Scholar
• 60 Biragyn A, Ruffini PA, Leifer CA , et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002; 298 (5595) 1025-1029
  CrossrefPubMedGoogle Scholar
• 61 Paone G, Lucantoni G, Leone A , et al. Human neutrophil peptides stimulate tumor necrosis factor-alpha release by alveolar macrophages from patients with sarcoidosis. Chest 2009; 135 (2) 586-587
  PubMedGoogle Scholar
• 62 Chen ES, Song Z, Willett MH , et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med 2010; 181 (4) 360-373
  CrossrefPubMedGoogle Scholar
• 63 Oswald-Richter KA, Culver DA, Hawkins C , et al. Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis. Infect Immun 2009; 77 (9) 3740-3748
  CrossrefPubMedGoogle Scholar
• 64 Pathak SK, Basu S, Basu KK , et al. Direct extracellular interaction between the early secreted antigen ESAT-6 of Mycobacterium tuberculosis and TLR2 inhibits TLR signaling in macrophages. Nat Immunol 2007; 8 (6) 610-618
  CrossrefPubMedGoogle Scholar
• 65 Murphy EE, Terres G, Macatonia SE , et al. B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation. J Exp Med 1994; 180 (1) 223-231
  CrossrefPubMedGoogle Scholar
• 66 Gabrilovich MI, Walrath J, van Lunteren J , et al. Disordered Toll-like receptor 2 responses in the pathogenesis of pulmonary sarcoidosis. Clin Exp Immunol 2013; 173 (3) 512-522
  CrossrefPubMedGoogle Scholar
• 67 Wikén M, Grunewald J, Eklund A, Wahlström J. Higher monocyte expression of TLR2 and TLR4, and enhanced pro-inflammatory synergy of TLR2 with NOD2 stimulation in sarcoidosis. J Clin Immunol 2009; 29 (1) 78-89
  CrossrefPubMedGoogle Scholar
• 68 Wikén M, Idali F, Al Hayja MA, Grunewald J, Eklund A, Wahlström J. No evidence of altered alveolar macrophage polarization, but reduced expression of TLR2, in bronchoalveolar lavage cells in sarcoidosis. Respir Res 2010; 11: 121
  CrossrefPubMedGoogle Scholar
• 69 Veltkamp M, Wijnen PA, van Moorsel CH , et al. Linkage between Toll-like receptor (TLR) 2 promotor and intron polymorphisms: functional effects and relevance to sarcoidosis. Clin Exp Immunol 2007; 149 (3) 453-462
  CrossrefPubMedGoogle Scholar
• 70 Hogan LH, Heninger E, Elsner RA , et al. Requirements for CD4(+) T cell levels in acute Mycobacterium bovis strain bacille Calmette Guerin (BCG)-induced granulomas differ for optimal mycobacterial control versus granuloma formation. Int Immunol 2007; 19 (5) 627-633
  CrossrefPubMedGoogle Scholar
• 71 Du Bois RM, Kirby M, Balbi B, Saltini C, Crystal RG. T-lymphocytes that accumulate in the lung in sarcoidosis have evidence of recent stimulation of the T-cell antigen receptor. Am Rev Respir Dis 1992; 145 (5) 1205-1211
  CrossrefPubMedGoogle Scholar
• 72 Müller-Quernheim J, Saltini C, Sondermeyer P, Crystal RG. Compartmentalized activation of the interleukin 2 gene by lung T lymphocytes in active pulmonary sarcoidosis. J Immunol 1986; 137 (11) 3475-3483
  PubMedGoogle Scholar
• 73 Devergne O, Emilie D, Peuchmaur M, Crevon MC, D'Agay MF, Galanaud P. Production of cytokines in sarcoid lymph nodes: preferential expression of interleukin-1 beta and interferon-gamma genes. Hum Pathol 1992; 23 (3) 317-323
  CrossrefPubMedGoogle Scholar
• 74 Richmond BW, Ploetze K, Isom J , et al. Sarcoidosis Th17 cells are ESAT-6 antigen specific but demonstrate reduced IFN-γ expression. J Clin Immunol 2013; 33 (2) 446-455
  CrossrefPubMedGoogle Scholar
• 75 Facco M, Cabrelle A, Teramo A , et al. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax 2011; 66 (2) 144-150
  CrossrefPubMedGoogle Scholar
• 76 Furusawa H, Suzuki Y, Miyazaki Y, Inase N, Eishi Y. Th1 and Th17 immune responses to viable Propionibacterium acnes in patients with sarcoidosis. Respir Investig 2012; 50 (3) 104-109
  PubMedGoogle Scholar
• 77 Ten Berge B, Paats MS, Bergen IM , et al. Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology (Oxford) 2012; 51 (1) 37-46
  CrossrefPubMedGoogle Scholar
• 78 Bianco A, Spiteri MA. Peripheral anergy and local immune hyperactivation in sarcoidosis: a paradox or birds of a feather. Clin Exp Immunol 1997; 110 (1) 1-3
  CrossrefPubMedGoogle Scholar
• 79 Hudspith BN, Brostoff J, McNicol MW, Johnson NM. Anergy in sarcoidosis: the role of interleukin-1 and prostaglandins in the depressed in vitro lymphocyte response. Clin Exp Immunol 1984; 57 (2) 324-330
  PubMedGoogle Scholar
• 80 Bansal AS, Bruce J, Hogan PG, Allen RK. An assessment of peripheral immunity in patients with sarcoidosis using measurements of serum vitamin D3, cytokines and soluble CD23. Clin Exp Immunol 1997; 110 (1) 92-97
  CrossrefPubMedGoogle Scholar
• 81 Mathew S, Bauer KL, Fischoeder A, Bhardwaj N, Oliver SJ. The anergic state in sarcoidosis is associated with diminished dendritic cell function. J Immunol 2008; 181 (1) 746-755
  CrossrefPubMedGoogle Scholar
• 82 Oswald-Richter KA, Richmond BW, Braun NA , et al. Reversal of global CD4+ subset dysfunction is associated with spontaneous clinical resolution of pulmonary sarcoidosis. J Immunol 2013; 190 (11) 5446-5453
  CrossrefPubMedGoogle Scholar
• 83 Miyara M, Amoura Z, Parizot C , et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 2006; 203 (2) 359-370
  CrossrefPubMedGoogle Scholar
• 84 Lee NS, Barber L, Kanchwala A , et al. Low levels of NF-κB/p65 mark anergic CD4+ T cells and correlate with disease severity in sarcoidosis. Clin Vaccine Immunol 2011; 18 (2) 223-234
  CrossrefPubMedGoogle Scholar
• 85 Mroz RM, Korniluk M, Stasiak-Barmuta A, Ossolinska M, Chyczewska E. Increased levels of Treg cells in bronchoalveolar lavage fluid and induced sputum of patients with active pulmonary sarcoidosis. Eur J Med Res 2009; 14 (Suppl. 04) 165-169
  PubMedGoogle Scholar
• 86 Wikén M, Grunewald J, Eklund A, Wahlström J. Multiparameter phenotyping of T-cell subsets in distinct subgroups of patients with pulmonary sarcoidosis. J Intern Med 2012; 271 (1) 90-103
  CrossrefPubMedGoogle Scholar
• 87 Rappl G, Pabst S, Riemann D , et al. Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation. Clin Immunol 2011; 140 (1) 71-83
  CrossrefPubMedGoogle Scholar
• 88 Taflin C, Miyara M, Nochy D , et al. FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. Am J Pathol 2009; 174 (2) 497-508
  CrossrefPubMedGoogle Scholar
• 89 Fehrenbach H, Zissel G, Goldmann T , et al. Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis. Eur Respir J 2003; 21 (3) 421-428
  CrossrefPubMedGoogle Scholar
• 90 Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 2005; 34 (5) (Suppl. 01) 34-38
  CrossrefPubMedGoogle Scholar
• 91 Baughman RP, Drent M, Kavuru M , et al; Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174 (7) 795-802
  CrossrefPubMedGoogle Scholar
• 92 Idali F, Wahlström J, Müller-Suur C, Eklund A, Grunewald J. Analysis of regulatory T cell associated forkhead box P3 expression in the lungs of patients with sarcoidosis. Clin Exp Immunol 2008; 152 (1) 127-137
  CrossrefPubMedGoogle Scholar
• 93 Liu G, Ma H, Qiu L , et al. Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+ T cells in mice. Immunol Cell Biol 2011; 89 (1) 130-142
  CrossrefPubMedGoogle Scholar
• 94 Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S, Taams LS. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci U S A 2007; 104 (49) 19446-19451
  CrossrefPubMedGoogle Scholar
• 95 Prasse A, Pechkovsky DV, Toews GB , et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 2006; 173 (7) 781-792
  CrossrefPubMedGoogle Scholar
• 96 Pechkovsky DV, Prasse A, Kollert F , et al. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. Clin Immunol 2010; 137 (1) 89-101
  CrossrefPubMedGoogle Scholar
• 97 Cai M, Bonella F, He X , et al. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases. Respir Med 2013; 107 (9) 1444-1452
  CrossrefPubMedGoogle Scholar
• 98 Julian MW, Shao G, Schlesinger LS , et al. Nicotine treatment improves Toll-like receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis. Chest 2013; 143 (2) 461-470
  CrossrefPubMedGoogle Scholar
• 99 Valeyre D, Soler P, Clerici C , et al. Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease. Thorax 1988; 43 (7) 516-524
  CrossrefPubMedGoogle Scholar
• 100 Hattori T, Konno S, Shijubo N, Ohmichi M, Nishimura M. Increased prevalence of cigarette smoking in Japanese patients with sarcoidosis. Respirology 2013; 18 (7) 1152-1157
  PubMedGoogle Scholar
• 101 Gupta D, Singh AD, Agarwal R, Aggarwal AN, Joshi K, Jindal SK. Is tobacco smoking protective for sarcoidosis? A case-control study from North India. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27 (1) 19-26
  PubMedGoogle Scholar
• 102 Delgado M, Gomariz RP, Martinez C, Abad C, Leceta J. Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. Eur J Immunol 2000; 30 (11) 3236-3246
  CrossrefPubMedGoogle Scholar
• 103 Delgado M, Ganea D. Vasoactive intestinal peptide inhibits IL-8 production in human monocytes. Biochem Biophys Res Commun 2003; 301 (4) 825-832
  CrossrefPubMedGoogle Scholar
• 104 Prasse A, Zissel G, Lützen N , et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med 2010; 182 (4) 540-548
  CrossrefPubMedGoogle Scholar
• 105 Lyons DJ, Donald S, Mitchell DN, Asherson GL. Chemical inactivation of the Kveim reagent. Respiration 1992; 59 (1) 22-26
  CrossrefPubMedGoogle Scholar
• 106 Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest 2003; 124 (5) 2028-2031
  CrossrefPubMedGoogle Scholar
• 107 Okamoto Yoshida Y, Umemura M, Yahagi A , et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 2010; 184 (8) 4414-4422
  CrossrefPubMedGoogle Scholar
• 108 Zhang Y, Chen L, Gao W , et al. IL-17 neutralization significantly ameliorates hepatic granulomatous inflammation and liver damage in Schistosoma japonicum infected mice. Eur J Immunol 2012; 42 (6) 1523-1535
  CrossrefPubMedGoogle Scholar